LNCaP: Difference between revisions
CSV import |
|||
| Line 35: | Line 35: | ||
* [[PC-3]] | * [[PC-3]] | ||
* [[DU145]] | * [[DU145]] | ||
== See also == | == See also == | ||
Latest revision as of 20:30, 21 February 2025
Human prostate cancer cell line
Overview[edit]

LNCaP is a human prostate cancer cell line commonly used in cancer research. It was established from a metastatic lesion of human prostatic adenocarcinoma in the left supraclavicular lymph node of a 50-year-old Caucasian male. LNCaP cells are androgen-sensitive, meaning their growth is stimulated by androgens, which are male hormones such as testosterone.
Characteristics[edit]
LNCaP cells exhibit several key characteristics that make them valuable for research:
- Androgen Sensitivity: LNCaP cells require androgens for optimal growth, making them a model for studying androgen-dependent prostate cancer.
- PSA Production: These cells produce prostate-specific antigen (PSA), a protein used as a marker in prostate cancer diagnosis and monitoring.
- Mutation Profile: LNCaP cells have a mutation in the androgen receptor gene, which affects their response to androgens.
Applications in Research[edit]

LNCaP cells are widely used in prostate cancer research to:
- Study the mechanisms of androgen receptor signaling and its role in prostate cancer progression.
- Investigate the effects of anti-androgen drugs and other therapeutic agents.
- Explore the molecular pathways involved in prostate cancer metastasis and resistance to therapy.
Comparison with Other Cell Lines[edit]
LNCaP cells are often compared with other prostate cancer cell lines such as PC-3 and DU145. Unlike LNCaP, PC-3 and DU145 are androgen-independent, meaning they do not require androgens for growth. This difference makes LNCaP particularly useful for studying the transition from androgen-dependent to androgen-independent prostate cancer.
Limitations[edit]
While LNCaP cells are a valuable tool in prostate cancer research, they have limitations:
- Genetic Drift: Over time, LNCaP cells can undergo genetic changes that may affect experimental outcomes.
- Limited Metastatic Potential: LNCaP cells have a lower metastatic potential compared to other cell lines, which may limit their use in studying advanced prostate cancer.